ArticleFrontiers in pharmacology2025
Pharmacovigilance-related events, disease burden and overall efficiency of care in european countries, 1990-2021.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate and compare the disease burden of pharmacovigilance-related events in European countries, to identify the factors related to pharmacovigilance-related inputs in various countries, and to analyze and compare the comprehensive benefits of pharmacovigilance-related events in various countries. Methods: Using the Global Burden of Disease Study 2021 database, we combined information on adverse effects of medical treatment and drug use disorders to identify all pharmacovigilance-related events. We used principal component analysis to synthesize six first-level indicators to compare the burden of disease in each country in each year. We used data envelopment analysis to compare the efficiency of pharmacovigilance in each country. Results: In 2021, the Quality of care index for pharmacovigilance-related events was highest in Northern and Western European countries. Looking at data from 1990 to 2021, the change node of this index in most countries occurred around 2000 to 2010, and the value changed steadily. Countries with relatively low investment in health resources and less experience in the supervision of adverse drug reactions have higher comprehensive benefits of nursing for pharmacovigilance-related events. Conclusion: The effect of the development of a system for pharmacovigilance has a hysteresis. The disease burden is affected by various factors such as population aging, human resource investment, and medical and health needs, and the policy is highly dominant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.